MARKET

TTOO

TTOO

T2 Biosystems
NASDAQ
5.30
-0.13
-2.39%
After Hours: 5.30 0 0.00% 19:41 02/27 EST
OPEN
5.40
PREV CLOSE
5.43
HIGH
5.42
LOW
5.11
VOLUME
133.07K
TURNOVER
0
52 WEEK HIGH
70.00
52 WEEK LOW
3.360
MARKET CAP
21.47M
P/E (TTM)
-0.0190
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TTOO last week (0219-0223)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Applied Therapeutics stock rose 42.5% to $5.34 during Monday's regular session. Universe Pharmaceuticals (NASDAQ:UPC) shares moved upwards by 41.86%. AMN Healthcare Services (NYSE:AMN) stock declined by 20.7% during the session.
Benzinga · 02/19 17:30
Weekly Report: what happened at TTOO last week (0212-0216)?
Weekly Report · 02/19 09:00
12 Health Care Stocks Moving In Friday's Intraday Session
OneMedNet (NASDAQ:ONMD) shares rose 91.2% to $1.44 during Friday's regular session. Applied Therapeutics stock increased by 28.53% and Ocugen shares moved upwards by 21.98%. AMN Healthcare Services (NYSE:AMN) shares declined by 18.9% during the daily session. Cross Country Healthcare and T2 Biosystems among the losers.
Benzinga · 02/16 17:31
T2 Biosystems, AMN Healthcare Services among healthcare movers
Seeking Alpha · 02/16 15:00
12 Health Care Stocks Moving In Friday's Pre-Market Session
China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 25.2% to $2.73 during Friday's pre-market session. Sarepta Therapeutics shares moved upwards by 14.5%. MediciNova stock rose by 17.77% as the company's Q4 earnings report came out yesterday. Losers Inventiva and T2 Biosystems also lost ground.
Benzinga · 02/16 13:06
T2 Biosystems’ Strong Financials and Strategic Growth Moves
TipRanks · 02/15 22:07
T2 Biosystems Announces Preliminary Q4 Revenue Of $1.7M Vs $2.4M Est.; FY23 Revenue Of $7.2M Vs $7.9M Est.; FY24 Revenue Of $10M-$11M Vs $10.8M Est
T2 Biosystems, Inc. Announces preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2023. The company is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. The Company achieved record sales of the T2Bacteria Panel in the U.S. In 2023 and expects full year 2024 revenue of $11.0 million.
Benzinga · 02/15 21:24
More
About TTOO
T2 Biosystems, Inc. is an in-vitro diagnostics company. The Company is focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. The Company is using its T2MR technology, which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its primary commercial products include the T2Candida Panel and the T2Bacteria Panel. Its T2Candida Panel is a direct-from-blood test that identifies the lethal form of common bloodstream infections that cause sepsis and candidemia. Its T2Bacteria Panel is a direct-from-blood test that detects certain bacterial pathogens associated with sepsis. Its primary commercial products also include the T2Dx Instrument, the T2Resistance Panel, and the T2SARS-CoV-2 Panel.

Webull offers T2 Biosystems Inc stock information, including NASDAQ: TTOO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTOO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TTOO stock methods without spending real money on the virtual paper trading platform.